Clopidogrel: a case for indication-specific pharmacogenetics.
Clin Pharmacol Ther
; 91(5): 774-6, 2012 May.
Article
em En
| MEDLINE
| ID: mdl-22513313
ABSTRACT
The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ticlopidina
/
Inibidores da Agregação Plaquetária
/
Hidrocarboneto de Aril Hidroxilases
/
Angioplastia Coronária com Balão
Limite:
Humans
Idioma:
En
Revista:
Clin Pharmacol Ther
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Estados Unidos